Crewe Advisors’s Xenetic Biosciences XBIO Stock Holding History

Crewe Advisors’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12	Closed	–	–	1308
2022 Q3	$0	Hold	12	–	–	﹤0.01%	1286
2022 Q2	$0	Hold	12	–	–	﹤0.01%	1164
2022 Q1	$0	Hold	12	–	–	﹤0.01%	505
2021 Q4	$0	Hold	12	–	–	﹤0.01%	468
2021 Q3	$0	Hold	12	–	–	﹤0.01%	471
2021 Q2	$0	Hold	12	–	–	﹤0.01%	488
2021 Q1	$0	Hold	12	–	–	﹤0.01%	488
2020 Q4	$0	Hold	12	–	–	﹤0.01%	655
2020 Q3	$0	Hold	12	–	–	﹤0.01%	640
2020 Q2	$0	Hold	12	–	–	﹤0.01%	229
2020 Q1	$0	Hold	12	–	–	﹤0.01%	249
2019 Q4	$0	Hold	12	–	–	﹤0.01%	281
2019 Q3	$0	Buy	+12	New	+$429	﹤0.01%	313

Other funds holding XBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Crewe Advisors's XBIO Position: Q4 2022 in Review

Crewe Advisors sold out of Xenetic Biosciences (XBIO) in Q4 2022, closing a stake of 12 shares.

Crewe Advisors first reported a position in XBIO in Q3 2019 and held it in 13 quarters. The position peaked at $0 in Q3 2022. 19 funds tracked by Wall St. Rank hold XBIO as of Q4 2022.

Crewe Advisors reported no remaining Xenetic Biosciences position as of Q4 2022 after selling out during the quarter.
Crewe Advisors sold 12 Xenetic Biosciences shares in Q4 2022.
Crewe Advisors first reported a position in Xenetic Biosciences in Q3 2019 and held it in 13 quarters.
Crewe Advisors's Xenetic Biosciences position peaked at $0 in Q3 2022.
19 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q4 2022.

Based on Crewe Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.